Summary

Eligibility
for people ages up to 30 years (full criteria)
Location
at UCSF
Dates
study started
completion around

Description

Summary

This phase II trial studies the side effects and how well larotrectinib works in treating patients with previously untreated TRK fusion solid tumors and TRK fusion acute leukemia that has come back. Larotrectinib may stop the growth of cancer cells with TRK fusions by blocking the TRK enzymes needed for cell growth.

Official Title

Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias

Details

Keywords

Central Nervous System Neoplasm, Infantile Fibrosarcoma, Recurrent Acute Leukemia, Refractory Acute Leukemia, Solid Neoplasm, Larotrectinib, TRK fusion, NTRK fusion, Leukemia, Neoplasms, Nervous System Neoplasms, Central Nervous System Neoplasms, Fibrosarcoma, Acute Disease, Larotrectinib Sulfate

Eligibility

Locations

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Children's Oncology Group
ID
NCT03834961
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 31 people participating
Last Updated